文献速递青光眼

脉络膜上腔压力传感器系统的长期安全性与性能:EYEMATE-SC 试验随访研究结果

Long-term Safety and Performance of a Suprachoroidal Pressure Sensor System: Results of the EYEMATE-SC Trial Follow-up Study.
PubMed 文献 · Ophthalmology · 2025-01-31

本研究为前瞻性、开放标签、多中心介入性 EYEMATE-SC 试验的 3 年随访,纳入 22 例开角型青光眼患者(22 眼),在非穿透性青光眼手术中植入 EYEMATE-SC 脉络膜上腔传感器系统。结果显示该系统长期安全性良好,无严重不良事件或器械相关不良事件,其眼压测量与 Goldmann 压平眼压计的一致性在监管机构设定的标准范围内。

要点

  • 22 眼在非穿透性青光眼手术中植入 EYEMATE-SC 传感器,平均随访 2.7±0.6 年(范围 1.0-3.4 年)。
  • 无严重不良事件或器械相关不良事件;最常见不良事件为眼压升高 5 例、视力下降 3 例、白内障 3 例。

核心结论

  • 本研究显示 EYEMATE-SC 系统具有长期安全性,未观察到与 EYEMATE-SC 相关的严重不良事件。
  • EYEMATE-SC 与 Goldmann 压平眼压计的一致性处于监管机构设定的眼压测量方法标准范围内。
  • EYEMATE-SC 系统耐受性良好,可准确用于全天自我眼压测量。

研究设计与样本

  • 本研究为前瞻性、开放标签、多中心介入性 EYEMATE-SC 试验的 3 年随访研究。
  • 纳入 22 例开角型青光眼患者的 22 眼,在非穿透性青光眼手术中植入 EYEMATE-SC 脉络膜上腔传感器系统。
  • 所有患者在植入后第 12 至 36 个月期间接受 5 次随访,每次随访包括 EYEMATE-SC 系统与 Goldmann 压平眼压计的眼压测量及不良事件记录。

主要发现

  • 在 EYEMATE-SC 试验的 24 例合格患者中,纳入 22 例患者(平均年龄 65.0±10.6 岁,54.5% 为女性),总体平均随访 2.7±0.6 年(范围 1.0-3.4 年)。
  • Goldmann 压平眼压计与 EYEMATE-SC 眼压测量的一致性界限为 -6.2 至 5.7 mmHg(平均绝对差 2.3 mmHg)。
  • 12 个月时一致性相关系数 rccc=0.802(N=22),18 个月时 rccc=0.854(N=19)。
  • 在 86 对配对测量中,超过 85% 的测量差值小于 5 mmHg。
  • 未记录到严重不良事件或器械相关不良事件;最常见不良事件为眼压升高 5 例、视力下降 3 例、白内障 3 例。

关键数值与推荐

  • EYEMATE-SC 与 Goldmann 压平眼压计的一致性界限为 -6.2 至 5.7 mmHg,平均绝对差 2.3 mmHg。
  • 12 个月时一致性相关系数 rccc=0.802(N=22),18 个月时 rccc=0.854(N=19)。
  • 86 对配对测量中超过 85% 的差值小于 5 mmHg。

临床怎么用

  • EYEMATE-SC 系统耐受性良好,可准确用于全天自我眼压测量。
  • 原文未据此给出其他临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the long-term safety and performance of the EYEMATE-SC sensor system, a suprachoroidal implantable diagnostic medical device designed for measuring intraocular pressure (IOP) in patients with glaucoma that offers direct digitized IOP readings in millimeters of mercury. DESIGN: This study is part of the prospective, open-label, multicenter interventional EYEMATE-SC trial. PARTICIPANTS: Twenty-two eyes of 22 patients with open-angle glaucoma who received the implant in conjunction with nonpenetrating glaucoma surgery (NPGS) were included in the study. METHODS: This 3-year follow-up study analyzed the long-term safety of the EYEMATE-SC suprachoroidal sensor system (Implandata). The telemetric sensor system includes an implantable IOP sensor and a handheld reading device. MAIN OUTCOME MEASURES: All patients underwent 5 follow-up visits over a 24-month follow-up period from month 12 to month 36 after implantation. Each visit consisted of a comprehensive examination including IOP measurement with the EYEMATE-SC system and Goldmann applanation tonometry (GAT). The agreement between GAT and the EYEMATE-SC was analyzed using Bland-Altman analysis. Adverse events (AEs) and device-related adverse events (ADEs) were recorded at all follow-up visits. RESULTS: Of 24 eligible patients of the EYEMATE-SC trial, 22 patients (mean age 65.0 ± 10.6 years, 54.5% female) were enrolled. The overall mean follow-up was 2.7 ± 0.6 years (range, 1.0-3.4 years). Limits of agreement between GAT and EYEMATE-SC IOP were -6.2 to 5.7 mmHg (mean absolute difference of 2.3 mmHg), with greatest concordance at 12 months (concordance correlation coefficient [rccc] = 0.802, N = 22) and 18 months (rccc = 0.854, N = 19). A difference of < 5 mmHg was recorded in > 85% of the 86 paired measurements. No serious AEs and ADEs were recorded. Most common AEs were raised IOP in 5 patients, reduced visual acuity in 3 patients, and cataract in 3 patients. CONCLUSIONS: This study demonstrates the long-term safety of the EYEMATE-SC system. No serious AEs related to the EYEMATE-SC were observed. The agreement between the EYEMATE-SC and GAT was within the standard range of IOP-measuring methods set by regulatory agencies. The EYEMATE-SC system is well tolerated and accurate for self- measurement of IOP throughout the day. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Micheletti E, Mansouri K, Dick HB, et al. Long-term Safety and Performance of a Suprachoroidal Pressure Sensor System: Results of the EYEMATE-SC Trial Follow-up Study. Ophthalmology. 2025. PMID: 39892748. doi:10.1016/j.ophtha.2025.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。